4//SEC Filing
Vivo Ventures Fund V, L.P. 4
Accession 0000899243-17-029263
CIK 0001484565other
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 8:44 PM ET
Size
16.2 KB
Accession
0000899243-17-029263
Insider Transaction Report
Form 4
Vivo Ventures V, LLC
10% Owner
Transactions
- Purchase
Common Stock
2017-12-15$1.84/sh+1,072,888$1,976,796→ 3,888,137 total(indirect: See footnote) - Purchase
Common Stock Warrant (Right to Buy)
2017-12-15+9,318→ 9,318 total(indirect: See footnote)Exercise: $2.00From: 2017-12-15→ Common Stock (9,318 underlying) - Purchase
Common Stock Warrant (Right to Buy)
2017-12-15+793,937→ 793,937 total(indirect: See footnote)Exercise: $2.00From: 2017-12-15→ Common Stock (793,937 underlying) - Purchase
Common Stock
2017-12-15$1.84/sh+12,592$23,201→ 45,667 total(indirect: See footnote)
Transactions
- Purchase
Common Stock
2017-12-15$1.84/sh+12,592$23,201→ 45,667 total(indirect: See footnote) - Purchase
Common Stock Warrant (Right to Buy)
2017-12-15+9,318→ 9,318 total(indirect: See footnote)Exercise: $2.00From: 2017-12-15→ Common Stock (9,318 underlying) - Purchase
Common Stock
2017-12-15$1.84/sh+1,072,888$1,976,796→ 3,888,137 total(indirect: See footnote) - Purchase
Common Stock Warrant (Right to Buy)
2017-12-15+793,937→ 793,937 total(indirect: See footnote)Exercise: $2.00From: 2017-12-15→ Common Stock (793,937 underlying)
Vivo Ventures Fund V, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2017-12-15$1.84/sh+12,592$23,201→ 45,667 total(indirect: See footnote) - Purchase
Common Stock
2017-12-15$1.84/sh+1,072,888$1,976,796→ 3,888,137 total(indirect: See footnote) - Purchase
Common Stock Warrant (Right to Buy)
2017-12-15+793,937→ 793,937 total(indirect: See footnote)Exercise: $2.00From: 2017-12-15→ Common Stock (793,937 underlying) - Purchase
Common Stock Warrant (Right to Buy)
2017-12-15+9,318→ 9,318 total(indirect: See footnote)Exercise: $2.00From: 2017-12-15→ Common Stock (9,318 underlying)
Footnotes (5)
- [F1]The securities are held directly by Vivo Ventures Fund V. L.P. ("Vivo Ventures Fund V"). The Reporting Person is the sole general partner of Vivo Ventures Fund V, and may be deemed to beneficially own such securities. The Reporting Person holds voting and dispositive power with respect to the securities held by Vivo Ventures Fund V. Edgar Engleman, Albert Cha and Frank Kung are members of the Reporting Person and disclaim beneficial ownership of the securities held by Vivo Ventures Fund V, except to the extent of any pecuniary interest therein.
- [F2]The securities are held directly by Vivo Ventures V Affiliates Fund L.P. ("Vivo Ventures V Affiliates Fund"). The Reporting Person is the sole general partner of Vivo Ventures V Affiliates Fund, and may be deemed to beneficially own such securities. The Reporting Person holds voting and dispositive power with respect to the securities held by Vivo Ventures V Affiliates Fund. Edgar Engleman, Albert Cha and Frank Kung are members of the Reporting Person and disclaim beneficial ownership of the securities held by Vivo Ventures V Affiliates Fund, except to the extent of any pecuniary interest therein.
- [F3]The warrant has a term of three years and, in the event of positive Phase III results for Diazoxide Choline Controlled-Release (DCCR) tablet in Prader-Willi syndrome (PWS), the warrant will expire 30 days from the announcement of such results.
- [F4]The reported securities are included within 1,072,888 units purchased by the Reporting Person for $1.8425 per unit. Each unit consists of one share of common stock and one warrant to acquire 74% of a share of common stock.
- [F5]The reported securities are included within 12,592 units purchased by the Reporting Person for $1.8425 per unit. Each unit consists of one share of common stock and one warrant to acquire 74% of a share of common stock.
Documents
Issuer
SOLENO THERAPEUTICS INC
CIK 0001484565
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001398937
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 8:44 PM ET
- Size
- 16.2 KB